2024

1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

   Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

2. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC

   Bone Marrow Transplantation

3. Clinical-Hematological Changes and Predictors of Severity in Acute Food Protein–Induced Enterocolitis Syndrome Reactions at Oral Food Challenge: A Multicenter Observational Study

   Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 9, pp. 2454-2467.e8

4. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

   Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

5. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER)

   Rheumatology International, Vol. 44, Núm. 11, pp. 2445-2455

6. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

   Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

7. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

   Endocrine-related cancer

8. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

   European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

9. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

   The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

10. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

11. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

12. Natural history and surgical outcomes of Rathke’s cleft cysts: a Spanish multicenter study

    Frontiers in Endocrinology, Vol. 15

13. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

14. Perceptions of key informant neurologists before implementing anti-amyloid drugs in the Spanish departments of neurology

    Journal of Alzheimer's disease : JAD, Vol. 102, Núm. 1, pp. 207-217

15. Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: results of a phase 1 clinical trial with 2-year follow-up

    Cytotherapy, Vol. 26, Núm. 6, pp. 632-640

16. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

17. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

18. Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes

    Genome Biology, Vol. 25, Núm. 1

19. Spanish cardiac catheterization and coronary intervention registry. 33rd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2023)

    Revista Espanola de Cardiologia, Vol. 77, Núm. 11, pp. 936-946

20. Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis

    Reumatologia Clinica, Vol. 20, Núm. 8, pp. 423-439